Navigation Links
Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
Date:9/16/2010

TCT 2010    

-- XIENCE V Data From the SPIRIT IV Trial to be Presented as a Late Breaking Trial on Sept. 23-- Abbott's Vascular Pipeline Presentations to Include Data on the MitraClip® System and the Bioresorbable Vascular Scaffold

ABBOTT PARK, Ill., Sept. 16 /PRNewswire-FirstCall/ --  Abbott (NYSE: ABT) today announced the company's schedule of key data presentations at the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., to be held Sept. 21 – 25. Highlights include late-breaking two-year data from SPIRIT IV, one of the largest randomized, head-to-head clinical trials between two drug eluting stents – Abbott's XIENCE V® Everolimus Eluting Coronary Stent System and Boston Scientific's TAXUS® Express Paclitaxel-Eluting Coronary Stent System. In addition, the company will present data on two key pipeline products: the first-of-its-kind MitraClip® system, an investigational device in the United States; and the bioresorbable vascular scaffold (BVS), currently under clinical investigation outside the United States.

"We continue to strengthen our leadership position in the treatment of vascular disease with significant new data that support our market-leading XIENCE V stent, which has become the gold standard of drug eluting stents around the world," said Robert Hance, senior vice president, vascular, Abbott. "We also continue to make progress with our industry leading vascular pipeline, and we look forward to presenting additional data on our key pipeline products, including the MitraClip system and our bioresorbable vascular scaffold."

Key presentations are as follows (all times are Eastern):

SPIRIT IV: Two-year results from SPIRIT IV will be presented by Gregg W. Stone, M.D.
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... BOSTON , December 15, 2014 ... and development company, is pleased to announce the grant ... States relating to its GPCR-focused drug discovery ... significantly strengthens the global patent estate covering Heptares, technologies ... The suite of patents recently granted by the US ...
(Date:12/13/2014)... , Dec. 12, 2014  Radiologists can ... to images, to their referring physicians, electronic health ... using carefully selected technology.  That ... Data Systems Corporation (ADS) at the recent Radiology ... The transmitting of radiology reports in this manner ...
(Date:12/13/2014)... PLAINSBORO, N.J. and INDIANAPOLIS , ... diabetes care, and Chip Ganassi Racing Teams (CGRT), today announced ... Nordisk as the primary sponsor of the No. 83 Novo ... in the Verizon IndyCar Series. Kimball, ... first and only licensed driver with diabetes in the history ...
Breaking Medicine Technology:Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7
... LTD. announced on August 20 that its collaborative study on ... Cholera and Enteric Diseases in Kolkata, India, showed that daily ... diarrhea in young children. An unprecedented large-scale study, ... Kolkata, was conducted. As a result, "Yakult" was shown to ...
... inflammation plays a surprising role reducing the level of infection caused ... patients and others with weakened immune systems. The drug, ... by enhancing the body,s ability to chew them up instead of ... to provoke an onslaught of harmful inflammation. Besides opening ...
Cached Medicine Technology:Daily Intake of 'Yakult' Is Efficacious in Reducing Incidence of Acute Diarrhea in Young Children 2Daily Intake of 'Yakult' Is Efficacious in Reducing Incidence of Acute Diarrhea in Young Children 3Old Drug Holds Promise Against Opportunistic Lung Bug 2Old Drug Holds Promise Against Opportunistic Lung Bug 3Old Drug Holds Promise Against Opportunistic Lung Bug 4
(Date:12/17/2014)... NY (PRWEB) December 17, 2014 Project ... who recently brought videos of MIT economist and Obamacare ... best-selling author James O’Keefe conducted the interview, which is ... stated that there was intentional mislabeling in the Affordable ... in the bill: A two-hundred-and-fifty billion dollar per year ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Greater participation in music classes ... Researchers followed kids in the nonprofit Harmony Project, ... in Los Angeles. Over two years, children who ... how the brain processes speech and reading, compared to ... benefits of active participation in music classes occurred in ...
(Date:12/15/2014)... Cancer researchers have just published an important new ... malignant pleural mesothelioma. Surviving Mesothelioma has just posted an ... here to read it now. , Doctors at ... New York’s Langone Medical Center performed complete genetic analyses ... an effort to pinpoint the genes that are most ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 OutMarket ... today released “ Social Media Cheat Sheets ,” a ... community that drives results on the top ten social ... program. It helps drive awareness, engagement, and customer service. ... marketers to make an impact on new networks and ...
(Date:12/15/2014)... December 15, 2014 Kathy McAfee, America's ... Women World Awards in the category of Best Blog ... award for her weekly career blog Networking Ahead ... to help professionals elevate their talent and influence through ... named after her book Networking Ahead for Business, has ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Music Classes Boost Language Skills, Study Says 2Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... Recommend Photochromic Lenses to Protect Eyes This Summer and ... Throughout the ... the dangers of extended sun exposure and its effects on the skin, ... survey conducted by,the New England Eye Institute and Transitions Optical found that ...
... to vote soon on legislation that would cut ... WASHINGTON, July 9 Seniors across Texas ... Advantage program in,legislation being considered in the U.S. ... from the Medicare Advantage program in Texas,alone and ...
... Additional Research Warranted on Impact of Medicare Modernization ... Shows Possibility of,Longer Wait Times for Patients in ... to a new study,released today in the July ... (JAMA), cancer patients experienced no major changes in ...
... 2006, a pneumococcal vaccine (Prevenar) was introduced in the ... experiences have been published in the journal Vaccine ... pneumococcal infections among young children. , Pneumococcus is ... young children, e.g. meningitis, blood poisoning and pneumonia. Most ...
... lumpectomy linked to depression, fear, study finds , , WEDNESDAY, ... who opt for breast-conserving cancer surgery say they now ... their quality of life, a new study says. , ... were twice as likely to fear their cancer returning ...
... Razadyne ER,from Tier 2 to Tier 3 When Generic Razadyne ... ... WALTHAM, Mass., July 9 Decision Resources, one of ... finds that the generic availability of,Shire/Janssen/Ortho McNeil,s Razadyne (galantamine) in ...
Cached Medicine News:Health News:Study Confirms Americans Place Their Vision at Risk Year Round 2Health News:Study Confirms Americans Place Their Vision at Risk Year Round 3Health News:Texas Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Global Access Project (GAP) Study Examining Patients' Access to Cancer Care Featured in the Journal of the American Medical Association (JAMA) 2Health News:Vaccinated infants well-protected against severe pneumococcal infection in Norway 2Health News:Breast-Conserving Surgery Leaves Many Cancer Patients Disappointed 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: